We are live on ! Find out more

AbbVie

ABBV

Market cap $466B

263.96 USD

-0.06

0.02%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

263.52

-0.44

0.17%

1 day

-0.02%

5 days

0.88%

1 month

1.95%

3 months

21.93%

6 months

26.7%

Year to date

15.11%

1 year

18.91%

5 years

148.08%

10 years

319.58%

About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Employees: 57,000

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 58.7%

Neutral 34.9%

Negative 6.3%

The Motley Fool

AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?

AbbVie's Qulipta could be racing toward another label expansion, given a recent clinical trial win. This new indication could make a meaningful impact on Qulipta's sales.

AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?

The Motley Fool

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie continues to diversify its revenue streams with successful expansions in immunology and aesthetics. Bristol-Myers Squibb maintains high net margins while offering a significantly lower valuation than many industry peers.

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026

New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive disorder (MDD) and bipolar I (BP-I) depression These findings provide additional evidence that the benefits observed with VRAYLAR in clinical trials can also be achieved in routine practice, where patients often have more complex treatment needs NORTH CHICAGO, Ill., Sept. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today presented new VRAYLAR® (cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major depressive disorder (MDD) and bipolar I disorder (BP-I).

AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026

The Dividend Kings Ranked By Quality Scores (September 2026)

Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank the Dividend Kings using my 9F Quality Scores, blending qualitative and quantitative factors for a robust, investment-grade assessment. ADP stands out as the best total-return candidate. It is undervalued, high-quality, and offering a strong projected dividend growth rate and Adjusted Chowder Number.

The Dividend Kings Ranked By Quality Scores (September 2026)

24/7 Wall Street

5 Stocks, 5 Different Industries, 1 Thing in Common: Reliable Income

A biopharma giant, a chip maker, a delivery network, a trash hauler, and an oncology powerhouse walk into the same portfolio for one reason, and it has nothing to do with chasing the highest yield.

5 Stocks, 5 Different Industries, 1 Thing in Common: Reliable Income

AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting

Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM) Additional presentations highlight research across the breadth of AbbVie's multiple myeloma portfolio, including ABBV-2001 (ISB 2001), a trispecific T-cell engager and surzetoclax, a BCL-2 inhibitor, and combination approaches AbbVie's IMS presence reinforces its strategy to build a differentiated multiple myeloma portfolio across complementary mechanisms designed to address disease complexity and evolving patient needs NORTH CHICAGO, Ill., Sept. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland.

AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting

Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications

Two studies evaluating targeted skincare and dermabrasion approaches will be presented at the 2026 Science of Skin Summit IRVINE, Calif., Sept. 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow® dermabrasion treatments in individuals taking medical weight loss (MWL) medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications

Zacks Investment Research

How AbbVie's Neuroscience Portfolio Has Transformed Over the Years

ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.

How AbbVie's Neuroscience Portfolio Has Transformed Over the Years

Zacks Investment Research

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

The Motley Fool

Is AbbVie the Best Dividend King to Buy in September?

AbbVie has a fantastic dividend track record. The company's rock-solid business should help maintain its dividend growth streak for a long time.

Is AbbVie the Best Dividend King to Buy in September?

See News Rankings

Price charts implemented using Lightweight Charts™